A: Monitoring the MA and CMA degradation of α-synuclein in cells derived from PD patients with GBA1 mutation to study α-synuclein degradation mediated by MA and CMA.D: An autophagy inducer (ambroxol) was used to assess autophagic flux and CMA.OR: (1) Protein expression of autophagy and autophagic flux markers (LC3II, LC3I, and p62) and CMA autophagy (LAMP2A and LAMP1) by Western blot. (2) Substrate degradation (α-synuclein) by immunostaining. This evidence concerns the gene LAMP1 and Parkinson disease.